- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04881487
Additional Treatment for Isolated Local Pancreatic Cancer Recurrence Using Stereotactic Body Radiation Therapy (ARCADE)
A Randomized Controlled Trial on Additional Treatment for Isolated Local Pancreatic Cancer Recurrence Using Stereotactic Body Radiation Therapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Rationale: Disease recurrence remains the main cause of mortality in patients who underwent resection for PDAC. In case of recurrence, patients are currently treated with palliative chemotherapy or best supportive care. In 20-30% of all patients, isolated local PDAC recurrence occurs after resection, which is frequently associated with considerable morbidity from local destructive tumor growth. Although survival after recurrence is predominantly determined by systemic disease, additional local ablative therapy might be of value to improve local disease control in these patients, which could positively affect survival and quality of life (QoL). Previously, radiation therapy has played only a minor role in the treatment of PDAC. As the pancreas is tightly surrounded by organs with limited radiation dose tolerance and subjected to abdominal motion due to respiration and peristalsis, optimal dose delivery has been impeded with conventional radiotherapy techniques. The development of image-guided stereotactic body radiation therapy (SBRT) techniques, however, enabled safe delivery of high irradiation doses to pancreatic lesions. Early retrospective studies have suggested that SBRT might lead to improved local control in patients with isolated local PDAC recurrence, potentially having a beneficial effect on both survival and QoL. In the current, multicenter randomized controlled trial, the value of SBRT in addition to standard of care in patients with isolated local PDAC recurrence is compared to standard of care alone, with regard to both survival and quality of life outcomes.
Objective: The main objective of this study is to improve survival after recurrence in patients with isolated local PDAC recurrence using local ablative treatment with SBRT in addition to standard of care. Furthermore, the effects of additional SBRT on QoL will be evaluated within this study.
Study design: A randomized controlled trial, nested within a prospective cohort (PACAP) according to the TwiCs design.
Study population: PACAP-participants with isolated local PDAC recurrence after primary resection who provided informed consent for being randomized in future studies.
Intervention: Local ablative therapy (5 times 8 Gray SBRT) in addition to standard of care.
Comparison: standard of care.
Main study endpoints: The main study endpoint is survival after recurrence. The most important secondary endpoint is quality of life. Other secondary endpoints are radiological treatment response, acute and late toxicity, overall, progression-free, local progression-free and distant metastasis free survival and reasons for non-eligibility or exclusion.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Utrecht, Netherlands, 3584 CX
- University Medical Center Utrecht
-
-
Noord-Holland
-
Amsterdam, Noord-Holland, Netherlands, 1081 HV
- Amsterdam University Medical Center, VUmc
-
-
Zuid-Holland
-
Rotterdam, Zuid-Holland, Netherlands, 3015 GD
- Erasmus University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participation in the PACAP cohort with written informed consent for being randomized in future studies
- Isolated local recurrence after primary PDAC resection
- Minimum age of 18 years
Exclusion Criteria:
- Distant metastases
- Expected lifespan < 3 months
- Ineligibility for MRI or CT according to the protocol of the local radiology department;
- Highly selective cases with resectable, isolated local recurrence without the need for either systemic or local ablative induction therapy, eligible for re-resection according to the expert panel.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Additional stereotactic body radiation therapy
SBRT in addition to standard of care.
|
5 fractions of 8 Gray stereotactic body radiation therapy in addition to standard of care.
|
No Intervention: Standard of care
Treatment according to current clinical practice.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Survival after recurrence
Time Frame: From the date of PDAC recurrence diagnosis until either death from any cause or last follow-u, whichever came first, assessed up to 24 months
|
The interval between the date of PDAC recurrence diagnosis and either death from any cause or last follow-up.
|
From the date of PDAC recurrence diagnosis until either death from any cause or last follow-u, whichever came first, assessed up to 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient reported Quality of Life as assessed using Exocrine Pancreatic Insufficiency (EPI) questionnaire
Time Frame: At baseline and at 3, 6, 9, 12, 18 and 24 months and every subsequent year after enrollment in the PACAP-cohort. Assessed through study completion, up to 18 months
|
Part of the Patient Reported Outcome Measures (PROMs) that are being standardly measured in PACAP-participants.
|
At baseline and at 3, 6, 9, 12, 18 and 24 months and every subsequent year after enrollment in the PACAP-cohort. Assessed through study completion, up to 18 months
|
Patient reported non-disease specific health-related Quality of Life (HRQoL) as assessed using the EQ-5D-5L
Time Frame: At baseline and at 3, 6, 9, 12, 18 and 24 months and every subsequent year after enrollment in the PACAP-cohort. Assessed through study completion, up to 18 months
|
Part of the Patient Reported Outcome Measures (PROMs) that are being standardly measured in PACAP-participants.
|
At baseline and at 3, 6, 9, 12, 18 and 24 months and every subsequent year after enrollment in the PACAP-cohort. Assessed through study completion, up to 18 months
|
Patient reported cancer-specific HRQoL as assessed using the EORTC QLQ-C30
Time Frame: At baseline and at 3, 6, 9, 12, 18 and 24 months and every subsequent year after enrollment in the PACAP-cohort. Assessed through study completion, up to 18 months
|
Part of the Patient Reported Outcome Measures (PROMs) that are being standardly measured in PACAP-participants.
|
At baseline and at 3, 6, 9, 12, 18 and 24 months and every subsequent year after enrollment in the PACAP-cohort. Assessed through study completion, up to 18 months
|
Patient reported tumor-specific HRQoL as assessed using the EORTC LQPAN26
Time Frame: At baseline and at 3, 6, 9, 12, 18 and 24 months and every subsequent year after enrollment in the PACAP-cohort. Assessed through study completion, up to 18 months
|
Part of the Patient Reported Outcome Measures (PROMs) that are being standardly measured in PACAP-participants.
|
At baseline and at 3, 6, 9, 12, 18 and 24 months and every subsequent year after enrollment in the PACAP-cohort. Assessed through study completion, up to 18 months
|
Patient reported chemotherapy-induced peripheral neuropathy as assessed using the EORTC QLQ-CIPN20
Time Frame: At baseline and at 3, 6, 9, 12, 18 and 24 months and every subsequent year after enrollment in the PACAP-cohort. Assessed through study completion, up to 18 months
|
Part of the Patient Reported Outcome Measures (PROMs) that are being standardly measured in PACAP-participants.
|
At baseline and at 3, 6, 9, 12, 18 and 24 months and every subsequent year after enrollment in the PACAP-cohort. Assessed through study completion, up to 18 months
|
Patient reported Quality of Life as assessed using the happiness, hospital, anxiety and depression scale (HADS)
Time Frame: At baseline and at 3, 6, 9, 12, 18 and 24 months and every subsequent year after enrollment in the PACAP-cohort. Assessed through study completion, up to 18 months
|
Part of the Patient Reported Outcome Measures (PROMs) that are being standardly measured in PACAP-participants.
|
At baseline and at 3, 6, 9, 12, 18 and 24 months and every subsequent year after enrollment in the PACAP-cohort. Assessed through study completion, up to 18 months
|
Patient reported Quality of Life as assessed using the worry of progression of cancer scale (WOPS)
Time Frame: At baseline and at 3, 6, 9, 12, 18 and 24 months and every subsequent year after enrollment in the PACAP-cohort. Assessed through study completion, up to 18 months
|
Part of the Patient Reported Outcome Measures (PROMs) that are being standardly measured in PACAP-participants.
|
At baseline and at 3, 6, 9, 12, 18 and 24 months and every subsequent year after enrollment in the PACAP-cohort. Assessed through study completion, up to 18 months
|
Treatment response assessed on CT-imaging (graded according to RECIST guidelines)
Time Frame: During and immediately after the intervention (SBRT treatment)
|
Response to SBRT treatment.
|
During and immediately after the intervention (SBRT treatment)
|
Acute and late toxicity of SBRT as assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
Time Frame: Through study completion, an average of 18 months
|
Assessed during regular follow-up moments.
In the intervention arm acute toxicity will be monitored by the treating radiation oncologist.
Acute toxicity will be defined as toxicity within 90 days from the end of SBRT treatment and will be assessed in week 1, 3, 6 and 12. Late toxicity is defined as toxicity occurring > 90 days from SBRT.
|
Through study completion, an average of 18 months
|
Overall survival
Time Frame: From the date of primary resection until the date of death from any cause or last follow-up, whichever came first, assessed up to 18 months
|
The interval between the date of primary resection and the date of death from any cause or last follow-up.
|
From the date of primary resection until the date of death from any cause or last follow-up, whichever came first, assessed up to 18 months
|
Progression-free survival
Time Frame: From the date of disease recurrence until the date that local and/or distant progression of disease occurs, assessed up to 18 months
|
The interval between the date of disease recurrence and the date that local and/or distant progression of disease occurs.
|
From the date of disease recurrence until the date that local and/or distant progression of disease occurs, assessed up to 18 months
|
Local progression-free survival
Time Frame: From the date of disease recurrence until the date that locoregional progression of disease occurs, assessed up to 18 months
|
The interval between the date of disease recurrence and the date that locoregional progression of disease occurs.
|
From the date of disease recurrence until the date that locoregional progression of disease occurs, assessed up to 18 months
|
Distant metastases free survival
Time Frame: From the date of disease recurrence until the date that distant progression of disease occurs, assessed up to 18 months
|
The interval between the date of disease recurrence and the date that distant progression of disease occurs.
|
From the date of disease recurrence until the date that distant progression of disease occurs, assessed up to 18 months
|
Reasons for non-eligibility or exclusion for SBRT treatment
Time Frame: At the time the patient is assessed eligible for the intervention. Assessed through the study, up to 18 months
|
e.g.
poor condition, patients wish, deteriorated condition, age.
|
At the time the patient is assessed eligible for the intervention. Assessed through the study, up to 18 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: I. Q. Molenaar, MD, PhD, Regional Academic Cancer Center Utrecht (RACU)
- Principal Investigator: M. P.W. Intven, MD, PhD, Regional Academic Cancer Center Utrecht (RACU)
- Principal Investigator: A. M.E. Bruynzeel, MD, PhD, Amsterdam University Medical Center, VUmc
- Principal Investigator: J. Nuyttens, MD, PhD, Erasmus Medical Center
- Principal Investigator: M. G.H. Besselink, MD, PhD, Amsterdam University Medical Center, AMC
- Principal Investigator: B. Groot Koerkamp, MD, PhD, Erasmus Medical Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NL74336.041.20
- 20-805 (Other Identifier: METC Utrecht)
- 12568 (Other Grant/Funding Number: KWF)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Pancreatic Ductal Adenocarcinoma
-
UMC UtrechtDutch Pancreatic Cancer Group (DPCG)Enrolling by invitationResectable Pancreatic Ductal Adenocarcinoma | Recurrent Pancreatic Ductal AdenocarcinomaNetherlands
-
Roswell Park Cancer InstituteNot yet recruitingStage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma | Advanced Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal Adenocarcinoma and other conditionsUnited States
-
Georgetown UniversityERYtech PharmaActive, not recruitingMetastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal AdenocarcinomaUnited States
-
Gilead SciencesTerminatedPreviously Untreated Pancreatic Ductal Adenocarcinoma | Relapsed/Refractory Pancreatic Ductal AdenocarcinomaUnited States
-
SOFIERecruitingFAP | PDAC - Pancreatic Ductal AdenocarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingBorderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal AdenocarcinomaUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingPancreatic Cancer | Pancreatic Ductal Adenocarcinoma | Metastatic Pancreatic Cancer | Metastatic Pancreatic Ductal Adenocarcinoma | Primary Pancreatic Ductal AdenocarcinomaUnited States
-
University Hospital Plymouth NHS TrustUniversity of PlymouthCompletedPancreatic Cancer | Surgery | Bile Duct Cancer | Pancreatic Ductal Adenocarcinoma | Survivorship | Cholangiocarcinoma, Extrahepatic | Cancer Recurrence | Recurrent Cancer | Pancreatic Ductal Carcinoma | Cholangiocarcinoma of the Extrahepatic Bile Duct | Ampullary Cancer | Cholangiocarcinoma Resectable | Cancer... and other conditionsSpain, United Kingdom, Australia, Austria, Italy, Mexico, Sudan, Pakistan
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Bristol-Myers SquibbRecruitingPancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)United States
-
OHSU Knight Cancer InstituteGenentech, Inc.; Oregon Health and Science University; American Association for... and other collaboratorsRecruitingStage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal AdenocarcinomaUnited States
Clinical Trials on Additional stereotactic body radiation therapy
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); Cancer Prevention Research Institute of TexasActive, not recruitingMetastatic Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8 | Malignant Neoplasms of Urinary Tract | Oligometastatic Renal Cell CarcinomaUnited States
-
Roswell Park Cancer InstituteCompletedLung CancerUnited States
-
University of Texas Southwestern Medical CenterCompletedPain | Unspecified Adult Solid Tumor, Protocol Specific | Metastatic CancerUnited States
-
Radiation Therapy Oncology GroupNational Cancer Institute (NCI); NRG OncologyCompletedLung CancerUnited States, Canada
-
NRG OncologyNational Cancer Institute (NCI)Active, not recruitingStage II Prostate AdenocarcinomaUnited States, Canada, Hong Kong, Switzerland, India, Ireland
-
Barts & The London NHS TrustBarts Cardiovascular CTU (Queen Mary University of London)Not yet recruitingHypertrophic CardiomyopathyUnited Kingdom
-
Erasmus Medical CenterCompletedKlatskin TumorNetherlands
-
Paul W. Read, MDUnknownMetastatic Bone LesionUnited States
-
University of FloridaCompletedSpinal TumorsUnited States
-
RPCR, Inc.CyberKnife CoalitionRecruitingDuctal Carcinoma in Situ | Invasive Ductal Carcinoma of Female BreastUnited States